ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

zanzalintinib

Also written as “Zanzalintinib” and “XL092”.

Its studies are mostly in Carcinoma, Renal Cell · Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Adenoma, Islet Cell, led by 3 companies.

Drug pageZanzalintinib: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 16, 202217 company-led studies, 15 open or runningNext primary completion: Dec 15, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Exelixisits history only1312 open or runningphase 3since Jun 16, 2022Feb 15, 2019Dec 15, 2026phase 3 · NCT05678673
Merck33 open or runningphase 3since Nov 7, 2025Jun 25, 2025Nov 27, 2030phase 3 · NCT07489495
Hoffmann-La Rocheits history only10 open or runningphase 2since Nov 7, 2017Nov 7, 2017none ahead

Also a collaborator on its studies: Bristol-Myers Squibb and Arcus Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 21, 2022Named zanzalintinibINNProposed as its International Nonproprietary Name in WHO's List 127 · before, XL092
  2. Jun 25, 2025First study: phase 2 study in Carcinoma, Renal CellFirst studyNCT07049926 · 140 planned · United States, Chile, France and more
  3. Nov 7, 2025Phase 3 study in Carcinoma, Renal CellNCT07227402 · 904 planned · United States, Argentina, Australia and more
  4. Mar 20, 2026Phase 3 study in Carcinoma, Renal CellNCT07489495 · 758 planned · United States, Argentina, Australia and more

Ahead

  1. Nov 27, 2030Primary completion: phase 3 study in Carcinoma, Renal CellNCT07489495
  2. Oct 26, 2031Primary completion: phase 2 study in Carcinoma, Renal CellNCT07049926
  3. Feb 27, 2032Primary completion: phase 3 study in Carcinoma, Renal CellNCT07227402

TargetBeta

“An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) hepatocyte growth factor receptor (c-Met; HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), AXL and MER, ”NCIt, by rule

Studies

All 3 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07489495Carcinoma, Renal Cell · United States, Argentina, Australia and more3RecruitingNov 27, 2030758
NCT07227402Carcinoma, Renal Cell · United States, Argentina, Australia and more3RecruitingFeb 27, 2032904
NCT07049926Carcinoma, Renal Cell · United States, Chile, France and more2RecruitingOct 26, 2031140

How it is read

Names in the registry

  • “Zanzalintinib”, 12 entries
  • “XL092”, 4 entries
  • “zanzalintinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.